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ABSTRACT 
Biomarkers are quantifiable indicators of disease. These surrogates should be specific, 
sensitive, predictive, robust and easily accessible. A major class of RNA described as non-coding RNA 
fulfils many of these criteria and recent studies have demonstrated that the two major sub-classes of 
non-coding RNA; long non-coding RNA and in particular, microRNA, are promising potential 
biomarkers. The ability to detect non-coding RNAs in biofluids has highlighted their usefulness as 
non-invasive markers of lung disease. Because expression of specific non-coding RNAs is altered in 
many lung diseases, and their levels in the circulation often reflect the changes in expression of their 
lung-specific counterparts, exploiting these biomolecules as diagnostic tools seems an obvious goal. 
New technology is driving developments in this area and there has been significant recent progress 
with respect to lung cancer diagnostics. The non-coding RNA biomarker field represents a clear 
example of modern day bench to bedside research. 
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One particularly surprising finding that has arisen from sequencing the human genome is 
that the number of protein-coding genes is considerably lower than expected. Although not 
precisely known, less than 2% of the genome actually encodes proteins. In light of this fact, the 
expression of non-coding RNA (ncRNA) is being examined with increased importance. ncRNA is a 
super-class of endogenous, non-protein coding RNA transcripts (Figure 1A), many of which have 
essential and very diverse biological functions in almost all cell processes. Based on their size, 
sequence and function, ncRNA can be classified into various discrete sub-classes, the two most 
notable of which are microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). Both species of 
ncRNA have vital roles in regulation of the genome; from transcription into messenger RNA (mRNA), 
to mRNA processing, to translation into protein. 
miRNAs are endogenous 18-25 nucleotide RNAs whose dominant function is to inhibit 
protein production (Figure 1B). miRNAs bind to target mRNAs in a sequence-specific manner; this 
leads to cleavage and degradation of the target mRNA and/or inhibition of  translation of the target 
mRNA into protein. A single miRNA and can regulate multiple genes, and most miRNAs have the 
ability to act as master regulators because each tends to target sets of genes that participate in 
molecular networks. Occasionally miRNAs can actually activate translation or directly regulate 
transcription. The more recently classified lncRNA group is loosely categorised by its length, which is 
any ncRNA over 200 nucleotides in length that is non-coding. lncRNAs have broad and wide-ranging 
regulatory functions in chromosomal configuration, RNA transcription and translation (Figure 1B) – 
this is possible due to their ability to bind to DNA, RNA or protein. Collectively, miRNA and lncRNA 
are believed to play roles in regulation at almost every level of gene expression and are crucial 
regulators of cell and tissue development and homeostasis.  
In the respiratory system many ncRNAs responsible for normal development and 
maintenance can become disease contributors if expressed aberrantly. This has important 
implications for major lung diseases, such as lung cancer, chronic obstructive pulmonary disease 
(COPD), pulmonary fibrosis, asthma and cystic fibrosis. A good example is the malexpression of miR-
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21, the most commonly expressed miRNA in the human lung, which at elevated levels can contribute 
to the symptomatic development of asthma, idiopathic pulmonary fibrosis and non-small cell lung 
cancer (NSCLC) through its effects on inflammatory and cancer-suppressing genes. Among lncRNAs 
the overexpression of MALAT-1 has a malignant impact on lung adenocarcinoma by regulating genes 
involved in metastasis. The disease-specific expression profiles of miR-21, MALAT-1 and many other 
ncRNAs can be detected in tissue and biofluids and can be used as disease biomarkers. 
 
miRNA biomarkers and lung cancer 
miRNA expression profiles in lung tumours are different compared to non-malignant tissue. 
Most research has focused on the pathological reasons and consequences for these aberrant 
expression profiles, however, many efforts have been made to exploit differential miRNA expression 
in lung cancer for diagnostic or prognostic purposes. This has resulted in the discovery of various 
miRNA expression ‘signatures’ that can identify specific types of lung cancer in lung biopsies. 
An ideal biomarker should, among other properties, be measurable with minimal 
invasiveness, risk and discomfort to the patient. Thus, screening biofluids such as blood, sputum or 
urine is favoured over more invasive techniques required to access lung biopsies, bronchial 
brushings or bronchoalveolar lavage fluid. Interestingly, miRNAs have been detected in all human 
biofluids, despite the hostile conditions of these environments which generally promote RNA 
degradation. Their relative stability in biofluids has given miRNAs a high potential as non-invasive 
biomarkers, particularly as an alternative to tumour biopsies. 
So far, more than 40 studies have been conducted to identify circulating miRNA profiles as 
diagnostic markers for lung cancer, with some showing specificities and sensitivities of >90% for 
differential profiles involving 10-40 miRNAs[1]. Some of the most prominently featured miRNAs in 
these profiles are miR-21, miR-210 and miR-155, all of which also have biological functions in lung 
cancer. 
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ncRNA biomarker discovery is generally performed with broad-range profiling methods such 
as microarrays, RT-PCR and next-generation sequencing that can measure the differential expression 
of up to thousands of ncRNAs (Figure 1C). With the advent of diagnostic ncRNA profiling, disease-
specific assay panels are now being designed that measure only the differential expression of 
miRNAs that are clinically relevant to the disease in question. This reduces both the cost and 
complexity of the assay.  
A number of companies have started to develop these clinical diagnostic test panels to 
classify various lung cancer types. Recently a lung cancer test has been developed that measures the 
expression of eight miRNAs in lung biopsies. This test has the ability to differentiate between small 
cell lung cancer and NSCLC types with very high sensitivity and specificity. Elsewhere plans are 
currently afoot to introduce a diagnostic circulating miRNA assay that can detect different lung 
cancers with 90% sensitivity and 80% specificity. Besides having the advantage of being a non-
invasive method of lung cancer diagnosis, nucleic acid assays, such as miRNA assays, enjoy 
favourable FDA regulatory guidelines for multiplexing compared to protein assays. This could make 
miRNA profiling more accurate and far more cost effective than protein assays. 
 
lncRNA biomarkers   
Although the expression of many lncRNAs has been evaluated in cancer and other 
respiratory diseases, their validation as diagnostic or prognostic biomarkers is at an earlier stage 
than that of their miRNA counterparts. Progress in non-lung cancers has been quicker in terms of the 
lncRNA biomarker discovery pipeline; the most advanced development being an FDA-approved PCA3 
assay which detects levels of the lncRNA PCA3 (prostate cancer antigen 3) in urine as a biomarker for 
prostate cancer. 
It is promising to note that lncRNAs have been easily isolated from bronchial brushings, 
biopsies and sputum. One caveat with respect to lncRNAs is that only a few species have been 
detected in biofluids. Thus more invasive sampling methods may be required, which is not to say 
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that a proportion that exist in biofluids may turn not out to be very useful circulating biomarkers due 
to their stability and ease of quantification. Good progress has been made in the discovery of 
potential lung cancer lncRNA biomarkers. At the time of writing, MALAT-1 (metastasis-associated 
lung adenocarcinoma transcript 1) appears to be one of the most promising candidates, especially as 
a biomarker of NSCLC[2] in tissue specimens. MALAT-1 is highly expressed in NSCLC and is a 
predictive marker for metastasis development and poor prognosis in this cancer, especially that 
arising from squamous cell carcinoma. Other promising lncRNAs whose expression is highly altered 
in lung cancer include CCAT2 and HOTAIR.  
 
Other lung diseases 
The development of ncRNA biomarker signatures for other respiratory diseases has not 
progressed at the same pace compared to the lung cancer field. However several studies are setting 
the groundwork for this. Specific circulatory miRNA signatures have been identified and validated in 
small sample sizes for chronic thromboembolic pulmonary hypertension, COPD, asthma, lung fibrosis 
and several infectious respiratory diseases[3-5]. For some of these, differential miRNA profiles are 
evident in bronchoalveolar lavage fluid and exhaled breath condensates (EBCs). Whether lncRNAs 
are detectable in EBCs has not yet been reported.  
 
Perspective 
Clearly, more studies are required for the robust identification and validation of diagnostic, 
prognostic and therapeutic ncRNA biomarkers. Current pharmaceutical developments are focused 
on lowering the cost and increasing the accuracy of ncRNA bioassays with new technologies such as 
single-molecule detection assays. Increased standardisation within the field of ncRNA biomarkers, 
such as finding reliable data normalisation factors, will also further enhance accuracy and 
reproducibility of results. The next five years is likely to produce a flurry of studies in this area. 
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Figure legend.  
Figure 1. Non-coding RNA classes, functions and biomarker potential  
(A) Classes of ncRNA, (B) function of miRNA and lncRNA and (C) Workflow for ncRNA biomarker 
discovery and validation. (1) Clinical samples are (2) profiled for ncRNA expression by various 
methods. (3) A clear ncRNA signature is identified in disease versus healthy samples and (4) 
validated in large independent patient and healthy control cohorts. BALF, bronchoalveolar lavage 
fluid; EBC, exhaled breath condensate; qPCR, quantitative polymerase chain reaction. 
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